Biomea Fusion, Inc. (BMEA): Shareholders' Equity
$29.55M
As of 2025-12-31
$12.14M
As of 2026-06-30
-35.2%
3-year compound annual growth
+41.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.55M | -42.7% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $51.57M | -69.5% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $169.24M | +55.9% | 2026-03-24, Balance as of period end |
| 2022-12-31 | $108.54M | -39.3% | 2025-03-31, Balance as of period end |
| 2021-12-31 | $178.78M | n/m | 2024-03-28, Balance as of period end |
| 2020-12-31 | $5.17M | n/m | 2023-03-28, Balance as of period end |
| 2019-12-31 | -$21.0K | n/a | 2022-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $29.55M | -42.7% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $25.98M | -77.1% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $27.98M | -55.3% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.22M | +273.5% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
Compare BMEA, RANI, SCYX, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗